PL2425016T3 - Środki i sposoby przeciwdziałania, zapobiegania i/lub określania niewydolności serca lub ryzyka niewydolności serca - Google Patents

Środki i sposoby przeciwdziałania, zapobiegania i/lub określania niewydolności serca lub ryzyka niewydolności serca

Info

Publication number
PL2425016T3
PL2425016T3 PL10769995T PL10769995T PL2425016T3 PL 2425016 T3 PL2425016 T3 PL 2425016T3 PL 10769995 T PL10769995 T PL 10769995T PL 10769995 T PL10769995 T PL 10769995T PL 2425016 T3 PL2425016 T3 PL 2425016T3
Authority
PL
Poland
Prior art keywords
heart failure
counteracting
risk
preventing
methods
Prior art date
Application number
PL10769995T
Other languages
English (en)
Inventor
Esther Elisa Johanna Maria Creemers
Yigal-Martin Pinto
Anke Johanna Marina Tijsen
Original Assignee
Academisch Medisch Centrum Bij De Univ Van Amsterdam
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/NL2009/050237 external-priority patent/WO2010126355A1/en
Application filed by Academisch Medisch Centrum Bij De Univ Van Amsterdam filed Critical Academisch Medisch Centrum Bij De Univ Van Amsterdam
Publication of PL2425016T3 publication Critical patent/PL2425016T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/10—Production naturally occurring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL10769995T 2009-04-29 2010-04-29 Środki i sposoby przeciwdziałania, zapobiegania i/lub określania niewydolności serca lub ryzyka niewydolności serca PL2425016T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/NL2009/050237 WO2010126355A1 (en) 2009-04-29 2009-04-29 Means and methods for counteracting, preventing and/or determining heart failure, or a risk of heart failure
EP09168764 2009-08-26
PCT/NL2010/050251 WO2010126370A2 (en) 2009-04-29 2010-04-29 Means and methods for counteracting, preventing and/or determining heart failure, or a risk of heart failure
EP10769995.1A EP2425016B1 (en) 2009-04-29 2010-04-29 Means and methods for counteracting, preventing and/or determining heart failure, or a risk of heart failure

Publications (1)

Publication Number Publication Date
PL2425016T3 true PL2425016T3 (pl) 2015-09-30

Family

ID=43032723

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10769995T PL2425016T3 (pl) 2009-04-29 2010-04-29 Środki i sposoby przeciwdziałania, zapobiegania i/lub określania niewydolności serca lub ryzyka niewydolności serca

Country Status (11)

Country Link
US (1) US20120115929A1 (pl)
EP (2) EP2425016B1 (pl)
JP (1) JP5871791B2 (pl)
KR (1) KR101758667B1 (pl)
CN (2) CN102421917B (pl)
AU (1) AU2010242163B2 (pl)
CA (1) CA2758928A1 (pl)
DK (1) DK2425016T3 (pl)
PL (1) PL2425016T3 (pl)
SG (1) SG175821A1 (pl)
WO (1) WO2010126370A2 (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2638159B1 (en) * 2010-11-11 2019-04-24 University of Miami Compositions, kits and methods for treatment of cardiovascular, immunological, and inflammatory diseases
WO2012110099A1 (en) * 2011-02-18 2012-08-23 Cavadis B.V. Determination of exosomal biomarkers for predicting cardiovascular events
WO2012110253A2 (en) * 2011-02-18 2012-08-23 Cavadis B.V. Exosomal biomarkers for cardiovascular events
BR112013029857A2 (pt) * 2011-05-24 2017-11-28 Mor Research Applic Ltd métodos e composições para determinação de insuficiência cardíaca ou risco de insuficiência cardíaca
ITRM20110685A1 (it) 2011-12-23 2013-06-24 Internat Ct For Genetic En Gineering And Microrna per la rigenerazione cardiaca attraverso l induzione della proliferazione dei miociti cardiaci
US8846316B2 (en) 2012-04-30 2014-09-30 Industrial Technology Research Institute Biomarker for human liver cancer
EP2682477A1 (en) * 2012-07-06 2014-01-08 National University of Ireland, Galway miR-181a and miR652 as oncologic biomarker of breast cancer
CN103571839B (zh) * 2012-07-26 2018-05-29 中国科学院上海药物研究所 具有转录和转录后双水平基因沉默功能的microRNA的筛选方法
CN104001186A (zh) * 2013-02-26 2014-08-27 中国科学院上海药物研究所 microRNA-552在预防和治疗酒精性肝病中的应用
WO2014187884A2 (en) * 2013-05-22 2014-11-27 Comprehensive Biomarker Center Gmbh Mirnas as non-invasive biomarkers for heart failure
US10634686B2 (en) * 2013-09-23 2020-04-28 University of Pittsburgh—of the Commonwealth System of Higher Education Biomarkers related to organ function
WO2015091907A1 (en) * 2013-12-19 2015-06-25 Comprehensive Biomarker Center Gmbh Determination of platelet-mirnas in heart failure
EP3146069B1 (en) * 2014-05-23 2018-04-25 Hummingbird Diagnostics GmbH Determination of mir-423-5p in heart failure
GB201418043D0 (en) * 2014-10-13 2014-11-26 Univ Leuven Kath MicroRNA signatures for cardiac disorders
US20180291374A1 (en) * 2014-11-12 2018-10-11 The General Hospital Corporation INHIBITORS OF MICRORNAs miR-155, miR-103, miR-105 and miR-107 THAT REGULATE PRODUCTION OF ATRIAL NATRIURETIC PEPTIDE (ANP) AS THERAPEUTICS AND USES THEREOF
WO2016133395A1 (en) 2015-02-20 2016-08-25 Rijksuniversiteit Groningen Circulating micrornas in patients with acute heart failure
CN105647919A (zh) * 2015-04-01 2016-06-08 四川大学华西医院 一种microRNA-129-5p的检测试剂盒和检测方法
WO2016182511A1 (en) * 2015-05-08 2016-11-17 Agency For Science, Technology And Research Method for diagnosis and prognosis of chronic heart failure
CN104988216B (zh) * 2015-06-08 2019-04-12 汪道文 慢性心力衰竭相关的血清miRNA及其应用
US10368774B2 (en) 2015-07-30 2019-08-06 Medtronic, Inc. Absolute intrathoracic impedance based scheme to stratify patients for risk of a heart failure event
CN105420376A (zh) * 2015-12-24 2016-03-23 北京泱深生物信息技术有限公司 与椎间盘退行性病变相关的微小rna
US11584932B2 (en) 2016-11-01 2023-02-21 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
CN107184594A (zh) * 2017-06-02 2017-09-22 青岛大学 miR‑142‑3p用于预防和/或治疗心脏疾病的组合物及应用
CN107858419A (zh) * 2017-11-10 2018-03-30 青岛大学 miRNA的应用、应用其的产品及检测方法
US20230265426A1 (en) * 2020-07-23 2023-08-24 Johann Wolfgang Goethe-Universität Frankfurt Combinatorial inhibition of mirnas for treatment of heart failure
CN113293207B (zh) * 2021-06-22 2022-09-02 上海市东方医院（同济大学附属东方医院） 外周血miRNA在制备作为心衰诊断或者预后的生物标志物中的用途
KR102747691B1 (ko) * 2021-09-16 2025-01-02 이화여자대학교 산학협력단 miRNA를 이용한 심방세동의 진단 또는 치료 용도

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0625049A4 (en) 1992-01-23 1995-07-12 Vical Inc EX VIVO GENTRANSFER.
EP0951544A2 (en) 1996-07-03 1999-10-27 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of human disease
US7632647B2 (en) 2001-04-13 2009-12-15 Biosite Incorporated Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
EP1666881B1 (en) 2001-05-04 2010-02-17 Biosite Incorporated Diagnostic markers of acute coronary syndromes and methods of use thereof
AU2005250432B2 (en) * 2004-05-28 2011-09-15 Asuragen, Inc. Methods and compositions involving microRNA
US7635563B2 (en) * 2004-06-30 2009-12-22 Massachusetts Institute Of Technology High throughput methods relating to microRNA expression analysis
CA2857881A1 (en) * 2004-11-12 2006-12-28 Asuragen, Inc. Methods and compositions involving mirna and mirna inhibitor molecules
EP1722232A1 (en) 2005-05-09 2006-11-15 F.Hoffmann-La Roche Ag Devices and methods for diagnosing or predicting early stage cardiac dysfunctions
SI2002003T1 (sl) 2005-05-27 2016-05-31 Ospedale San Raffaele S.R.L. Genski vektor, ki vsebuje mi-RNA
US20090306181A1 (en) * 2006-09-29 2009-12-10 Children's Medical Center Corporation Compositions and methods for evaluating and treating heart failure
US8906870B2 (en) * 2006-10-09 2014-12-09 Julius-Maximilians-Universitaet Wuerzberg MicroRNA (miRNA) for the diagnosis and treatment of heart diseases
WO2009012468A2 (en) * 2007-07-18 2009-01-22 The Regents Of The University Colorado Differential expression of micrornas in nonfailing versus failing human hearts
EP3112464A1 (en) * 2007-09-14 2017-01-04 The Ohio State University Research Foundation Mirna expression in human peripheral blood microvesicles and uses thereof
JP5654352B2 (ja) * 2007-11-09 2015-01-14 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム ｍｉＲ−１５ファミリーのマイクロＲＮＡによる心筋細胞生存及び心臓修復の調節
WO2010126355A1 (en) * 2009-04-29 2010-11-04 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for counteracting, preventing and/or determining heart failure, or a risk of heart failure

Also Published As

Publication number Publication date
AU2010242163A1 (en) 2011-11-17
KR20120041168A (ko) 2012-04-30
EP2907879A3 (en) 2015-10-14
EP2907879A2 (en) 2015-08-19
CN102421917A (zh) 2012-04-18
CA2758928A1 (en) 2010-11-04
WO2010126370A3 (en) 2011-09-29
CN104087662A (zh) 2014-10-08
EP2425016A2 (en) 2012-03-07
EP2425016B1 (en) 2015-04-01
KR101758667B1 (ko) 2017-07-18
SG175821A1 (en) 2011-12-29
US20120115929A1 (en) 2012-05-10
WO2010126370A2 (en) 2010-11-04
CN102421917B (zh) 2014-07-09
DK2425016T3 (en) 2015-06-29
JP5871791B2 (ja) 2016-03-01
JP2012525144A (ja) 2012-10-22
AU2010242163B2 (en) 2014-10-16

Similar Documents

Publication Publication Date Title
PL2425016T3 (pl) Środki i sposoby przeciwdziałania, zapobiegania i/lub określania niewydolności serca lub ryzyka niewydolności serca
EP2506802A4 (en) NON-INVASIVE IMPLANT RIP DETECTION SYSTEM
ZA201200947B (en) Medical history system
IL215975A (en) Heart failure device
EP2417591A4 (en) REDUCTION MEDICAL ERRORS
GB0905444D0 (en) Heart valve prosthesis
HUE055753T2 (hu) Szívbillentyû-protézis
ZA201108918B (en) Heart and/or steam activated valve and method therefor
IL219565A0 (en) Method for treating heart failure with stresscopin-like peptides
IL214747A0 (en) Method or system using biomarkers for the monitoring of a treatment
PL2693216T3 (pl) Sposób diagnozowania lub wstępnego diagnozowania beta-amyloidopatii
ZA201108855B (en) Wellness shoe and method
GB0900435D0 (en) Fail arrest system
PL2413800T3 (pl) Sposób określania poziomu kondycji fizycznej
HK1174292A (en) Methods and devices for treating heart failure